eli lilly stock - Search News

Eli Lilly Stock Rises

Eli Lilly’s Disappointing Quarter Was Already Baked In

Read a preview of Eli Lilly below and check back for more analysis soon. Investors already know what to expect when Eli Lilly formally reports its quarterly

Business Insider · 2d

Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before

The Motley Fool on MSN · 1d

Why Eli Lilly Stock Popped on Thursday

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in this morning's Q4 earnings report. Heading into the report, analysts forecast Lilly would earn $5.

Weight Loss Drug Demand Drives Eli Lilly Sales

Business Insider · 1d

Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become

Yahoo · 1d

Eli Lilly Earnings Top, 2025 Guidance Strong, But Weight-Loss Drug Sales Miss

Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.

U.S. News & World Report · 1d

Diabetes and Obesity Drugs Fuel Eli Lilly Profit in the Final Quarter of 2024

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast

Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly annual profit outlook tops expectations; stock gains

Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as ...

Eli Lilly Stock Rises After Earnings Beat, Upbeat Guidance

Eli Lilly stock rose after the drugmaker posted quarterly earnings that beat Wall Street expectations, and issued upbeat 2025 guidance. Fourth-quarter adjusted earnings came in at $5.32 a share, above ...

Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

1don MSN

Lilly says Mounjaro and Zepbound contributed to big revenue boost

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Eli Lilly Stock Rises

Weight Loss Drug Demand Drives Eli Lilly Sales

Related topics